Northwest Biotherapeutics is a biotechnology company that focuses on the clinical development of autologous immunotherapy products for cancer. The company s technology platform, DCVax, uses a patient s own dendritic cells. These cells are the starter engines of the immune system, which are loaded with tumor proteins or antigens. Injection of dendritic cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The company s two lead product candidates, DCVax-Prostate and DCVax-Brain, are in Food & Drug Administration-allowed late stage clinical trials, from which licensure is possible. Related products in the company s pipeline are also ready to enter Phase I clinical trials. Northwest Biotherapeutics is located in Bothell, Wash.